Tuesday, September 29, 2020 10:14:59 AM
Organicell Regenerative Medicine's Zofin nabs accelerated review in U.S. to treat COVID-19 patients
Sep. 29, 2020 10:11 AM ETOrganicell Regenerative Medicine, Inc. (BPSR)By: Meghavi Singh, SA News Editor
The FDA grants Zofin for the treatment of COVID-19 to Organicell Regenerative Medicine (OTCPK:BPSR -3.3%).
Zofin is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.
Alongside Convalescent Plasma, Zofin is the first reported acellular therapy under FDA’s approved expanded access program.
A 6 subject will be treated under emergency IND to evaluate significant improvement after being treated with Zofin.
The company will commence Phase I/II placebo controlled clinical trial and is in the process of recruit moderate to severe COVID-19 patients to evaluate the safety and potential efficacy of Zofin
Recent ZEOX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/14/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:05:15 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM